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Human papillomavirus (HPV) has been incriminated as the causal agent of cervical cancer which has been rated 
as the second most common cancers among women in developing countries and seventh most common cancers 
in the developed world. In spite of the fact that HPV has been the major cause of cervical cancer, the dilemma 
lies in finding a cost-effective therapy. Approximately 291 million women are infected with HPV worldwide, 32% 
of whom are infected with HPV16 or HPV18. The estimated prevalence of HPV in sub-Saharan Africa is 24% and 
11.7% globally. There have been studies reporting specific HPV prevalence rates in some part of Nigeria, with 
37% in Abuja, 10% in Port Harcourt, and 26.3% in Ibadan. In the Nigeria population, awareness of HPV infections 
is low, HPV vaccines are inadequate, and the cost of HPV vaccination per person is beyond what an average 
citizen can afford. It has been suggested that herbal therapy such as Echinacea therapy reduces HPV replication 
and enhances the immune system. Although there is yet no scientific proof of the efficacy of Echinacea therapy 
against HPV infections, future emphasis should be placed on scientific research into this alternative therapy. 
There is need for more studies on development of antiviral agents against HPV, with a prospect of easy 
accessibility and affordability in Nigeria. 
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Abstrait: 
Le papillomavirus humain (HPV) a été incriminé en tant qu'agent causal du cancer du col de l'utérus, classé 
comme le deuxième cancer le plus fréquent chez les femmes dans les pays en développement et le septième 
cancer le plus fréquent dans le monde développé. Malgré le fait que le VPH ait été la principale cause de cancer 
du col de l'utérus, le dilemme réside dans la recherche d'une thérapie rentable. Environ 291 millions de femmes 
sont infectées par le VPH dans le monde, dont 32% sont infectées par le VPH16 ou le VPH18. La prévalence 
estimée du VPH en Afrique subsaharienne est de 24% et 11,7% dans le monde. Des études ont signalé des taux 
de prévalence spécifiques du VPH dans une partie du Nigéria, avec 37% à Abuja, 10% à Port Harcourt et 26,3% 
à Ibadan. Dans la population nigériane, la sensibilisation aux infections au VPH est faible, les vaccins contre le 




VPH sont inadéquats et le coût de la vaccination contre le VPH par personne dépasse ce qu'un citoyen moyen 
peut se permettre. Il a été suggéré que la thérapie à base de plantes telle que la thérapie à l'échinacée réduit la 
réplication du VPH et renforce le système immunitaire. Bien qu'il n'y ait encore aucune preuve scientifique de 
l'efficacité de la thérapie à l'échinacée contre les infections au VPH, l'accent devrait être mis à l'avenir sur la 
recherche scientifique sur cette thérapie alternative. Il est nécessaire de poursuivre les études sur le 
développement d'agents antiviraux contre le VPH, avec une perspective d'accessibilité et de prix abordable au 
Nigéria. 
 
Mots-clés: Phytothérapie; HPV; Cancer du col utérin; Nigeria 
Introduction: 
 
 Human papillomavirus (HPV) is now 
recognised as the major aetiological factor of 
cervical cancer (CC), with more than 99.7% of 
the cases associated with prior oncogenic/high 
risk human papillomavirus (HrHPV). Infection 
with HrHPV is therefore, the primary risk 
factor for cervical cancer and the pre-
cancerous, cervical intraepithelial neoplasia 
(1). As HPV infection is a sexually transmitted 
infection, cervical cancer is now known as 
sexually transmitted cancer by origin (2). 
While infection with HrHPV is prevalent among 
sexually active women, it is usually transient 
and neutralised within 2 years of infection (3). 
A prospective study of 3,282 women in the 
Netherlands found that about 34% of young 
women failed to clear HPV in 2 years (4). The 
reported persistent rate of infection among 
women in Mainland China (age group 16-69 
years) was about 23% (5). 
 Human papilloma virus is one of the 6 
human viruses identified as Group 1 
(carcinogenic to humans) by the International 
Agency for Research on Cancer (IARC) (6,7). 
Worldwide, cervical cancer takes the lives of 
nearly 300,000 women a year, with more than 
80% from developing countries (8). Global 
HPV data show that Africa has the highest 
prevalence of 22.1% (9), with the lowest 
prevalence of 2.2% in Sudan (10). Cervical 
cancer is the most common gynaecological 
cancers in Nigeria, and the leading cause of 
cancer deaths among Nigerian women (11), 
where it is responsible for the death of one 
woman every hour and more than 9,000 
female patients annually (12).   
 Treatments for cervical HPV infections 
are restricted. The recommendations of the 
American Society for Colposcopy and Cervical 
Pathology (ASCCP) suggest that women with 
lesser cervical abnormalities such as HrHPV 
positive but cytologically negative, atypical 
Squamous Cell of Undetermined Significance 
(ASCUS), or Low Grade Squamous Intra-
epithelial Lesion (LGSIL) should be diagnosed 
through genotyping and testing of HrHPV 
within twelve months (13). Nevertheless, 
according to recent studies, the risk of 
developing malignant lesions will be increased 
with chronic carcinogenic infection (14). If 
infection with HrHPV persists for more than a 
year, 21% of women progressed to CIN2 (15). 
 There has been debate over the 
treatment of HrHPV positive people. Several 
researchers in Taiwan have proposed 
cryotherapy as one of the LGSIL’s treatment 
options, and a cohort study found that 
cryotherapy for women with LGSIL could 
minimize the incidence rate of CIN3+ by 
improving the clearance of HPV infections 
(16). In Nigeria some of the natural (herbal) 
remedies that have been used for the 
treatment of HPV infections include garlic, 
banana peel, apple cider vinegar, orange peel, 
potato, aloe vera, and pineapple. Although 
these have been used to treat warty HPV 
infections, they have not been used for HrHPV 
infections.    
Methodology: 
 Online databases were searched for 
available relevant documents written in 
English language up till January 15, 2019. 
These included African Biomedical databases, 
Nigerian Scientific Journals database, HPV 
Information Centre Registry, and PubMed 
Central (NCBI). The keywords for search were 
‘HPV’, ‘traditional treatment of HPV in Africa’, 
‘treatment of HPV in Nigeria’, ‘phytochemistry’ 
‘HPV awareness and vaccine in Nigeria’, and 
‘alternative medicine’.    
 We included original articles (cross 
sectional, prospective and randomized control 
trials), and review articles that provided 
information on current trends and meta-
analysis of HPV infection and treatment in 
Nigeria and globally. Independent reviewers 
evaluated the eligibility of each document for 
consideration and eliminated the likelihood of 
bias. A total of 58 citations and 18 articles 
were found eligible for the review.  
Prevalence of HrHPV infections in 
Nigeria    
 The prevalence of cervical HPV 
infection worldwide varies greatly, with some 
of the highest rates observed among African 
women. Approximately, two hundred and 
ninety-one million women are infected with 
HPV worldwide, 32% of whom are infected 
with HPV16 or HPV18 (9). The estimated 
prevalence of HPV infection in sub-Saharan 
Africa is 24%, and 11.7% globally (17). There 
have been studies reporting specific HPV 
prevalence rates in some parts of Nigeria, with 
37% in Abuja, 10% in Port Harcourt, and 




26.3% in Ibadan (18). In a population-based 
study conducted on women who have had 
sexual relations in their lifetime and their 
cervices examined by PCR and liquid based 
cytology, a 14.7% rate of high-risk HPV was 
detected in two third of the women (19). In 
another study conducted in north-eastern 
Nigeria, 48.7% of the women participants 
were positive for HPV type 18, 13.2% for 
HPV16, and 18.5% for combined HPV 31, 33 
and 35 (20).     
 In a similar prevalence study 
conducted in Ibadan, southwest Nigeria on 
932 sexually active women aged 15 years and 
above, 19.7% had HrHPV types 16, 31, 35, 
and 58 as the main HPV types, while 3.2% 
each had HPV types 16 and 35 (11). In Kano, 
northwest Nigeria, a hospital-based study 
conducted on 50 women aged 18 years and 
above to determine the prevalence of HPV 
infection using PCR for HPV DNA detection, 
76% of the study participants were positive 
for either HPV 16, 18 or both while 60.5% 
were co-infected with both HPV 16 and 18 
(21). In Nigeria, HPV infection tends to be 
predominantly reported in patients with high 
grade intraepithelial lesion as shown in Fig 1, 
although about 8% of the patients who have 
normal cytology had HPV infection, with 
higher prevalence among younger age group. 
Some biological mechanisms, such as 
immaturity of the cervix, insufficient cervical 
mucus production and increased cervical 
ectopia in younger women and adolescents, 
have been postulated to make them more 
susceptible to HPV infections (22). 
Preventive measures against cervical 
lesion in Nigeria   
 One of the most effective measures to 
prevent cervical cancer is to prevent HrHPV 
infection, and this can be achieved by 
administering vaccines such as Gardasil which 
target HPV 16, 18, 6 and 11 (23), Cervarix 
targeting HPV 16 and 18 (24), and Gardasil 9 
targeting HPV 31, 33, 45, 52 and 58. These 
vaccines reduces the chances of being infected 
with HPV when given to women before 
exposure to sexual activities. Nevertheless, 
these vaccines still have limitations in their 
failure to protect other HPV types not present 
in the vaccines. However, it is the most 
favoured method of prevention.  
 The vaccinations were approved and 
launched in Nigeria in 2009, with only a few 
affluent people taking up between 0 to 49% 
(25). In the Nigeria population, awareness of 
HPV infections and uptake of HPV vaccines is 
low, and the cost of HPV vaccination per 
person is beyond what an average Nigerian 
can afford (26). In the parts of Nigeria where 
the level of education is high, the female 
children caregivers showed very low 
knowledge on the risk factors associated with 
HPV infections and cervical cancer (27). While 
HrHPV infections are being treated by these 
vaccines, warts caused by low risk HPVs often 
regress without treatment, although these 
viruses are difficult to manage, as infection 
can reappear in the same site or in other 
places. Some of the current therapy for HPV 
infections are shown in Table 1. Although 
these medications are effective, they require 
multiple applications on the lesions. 
 
Fig 1.0: A pie chart showing Nigeria HPV prevalence in relation to Pap smear test 
Blue colour represents the HPV prevalence in people with normal cytology, red colour shows prevalence of HPV in people with 
low grade intraepithelial lesion, and green colour depicts HPV prevalence in High grade intraepithelial lesion, while the purple 









Table 1: Current treatment for HPV infection and its associated problem 
Current anti-HPV agents  Problem associated with the anti-HPV agents 
Gardasil     Effective for only those infected with the virus 
Cervarix     Inability to clear existing HPV infection 
Imiquimod   Severe itching, hives, and long treatment time (4 months).  
Condylox    Causes serious allergic reaction 
Cidofovir                     Expensive, side effects such as ocular disturbances  
Interferon           Have limited efficacy for high grade HPV associated lesions 
Podophyllotoxin   Not HPV-specific with up to 65% recurrence rate 
Heparin      Has an anticoagulant effect 
5-fluorouracil           Generates strong inflammatory response 
HPV therapeutic vaccines 
 Human papillomavirus therapeutic 
vaccines are administered to treat pre-
malignant and malignant lesions associated 
HPV, as opposed to Gardasil, Cervarix and 
Gardasil 9 vaccines, which are used to 
stimulate the development of L1 capsid pro- 
tein neutralizing antibodies. HPV therapeutic 
vaccines are administered in order to target 
onco-proteins such as E6 and E7 proteins, 
which are expressed by HPV throughout their 
life cycle, although these therapeutic vaccines 
are still in phase II and III clinical trial stages. 
An example of HPV therapeutic vaccine that 
has passed the clinical phase III evaluation is 
the MVA E2 which targets HPV16, and contains 
the bovine papilloma virus E2 protein. Since 
the E2 protein regulates the expression of E6 
and E7 onco-proteins, truncated E2 has 
negative regulatory gene to E6 and E7 
promoter sequence. Hindering the E6 and E7 
onco-proteins transcription in HPV infected 
cells thereby reduce progression to 
malignancy. Other HPV therapeutic vaccines 
are reported to have local mild to moderate 
side effects (28). 
Development of new anti-HPV agents 
from natural products   
 The recent major developments in 
medical treatment and biomedical technology 
includes various antiviral agents developed 
and used to treat infectious diseases, yet such 
progress has also led to the development of 
viral resistance strain. Hence it is necessary to 
develop new antiviral agents with various 
kinds of antiviral actions. The quest for novel 
antiviral agents is based not only on synthetic 
substances, but also on natural compounds 
such as herbal pharmaceutical products (29).
 Herbal products possess their own 
specific metabolites, which may identify 
variations between host and viral metabolism, 
contributing to antiviral activity. Most herbal 
pharmaceutical products can be easily 
obtained at a cheaper cost, and can be 
important for development of new antiviral 
agents with different antiviral activities than 
the current antivirals. The need to thoroughly 
investigate the causal agent associated with 
cases of cervical cancer is highly imperative, 
thus several diagnostic approaches are 
needed including the routine virological 
culture involving tissue culture screening (30-
32). Viral isolation could be carried out on 
either embroynated chicken egg (33,34) as 
well as cultivation on a continuous cell culture 
systems (35-39). Often, these situations were 
synonymous with an approach to establish 
cultures that improved biological products 
such as insulin for diabetic remedy employing 
the goats’ islets for xenotransplantation (40-
43). Similar scenario stands in the selection of 
suitable cells for study of apoptosis (44-46).
 The function of protein-receptor 
inhibitors used in in silico research is very 
important in drug design. Fig 2.0 summarises 
the steps to be taken to ensure herbal 
remedies are not only identified, but the 
mechanisms of actions can be properly 
understood. Recently countries like China 
have used detoxification therapy in the 
treatment of HPV, which tends to have 
positive effects on increasing HPV clearance 
rate, increasing the rate of CIN regression and 
influencing the proportion of certain immune 
cells, and also the level of cytokines in the 
genitalia following treatment (47). 
















































Potential herbal compounds as 
alternative for HPV infection therapy 
Silymarin:   
 Silymarin is an herbal antioxidant that 
is believed to have anti-cancer and anti-HPV 
properties (48). It is contained in milk thistle 
as an active agent and, possesses antioxidant 
properties. It was reported to induce apo- 
ptosis by modulating Bcl-2 family proteins and 
also activating caspase 3 (48). 
Curcumin (diferuloylmethane):  
 Curcumin is a polyphenol produced in 
the Curcuma longa plant, with a common 
name known as turmeric. For more than five 
decades, researches have shown that 
curcumin has onco-therapeutic effect with its 
antioxidative properties. Curcumin is a 
perennial herb which also possess anti-
inflammatory properties and was reported to 
down-regulates AP-1 and nuclear factor kappa 
light-chain enhancer of activated B cells both 
of which plays major role in HPV transcription 
(49). One research showed the therapeutic 
potential of curcumin in HrHPV oral cancer 
cells, with reported ability to selectively inhibit 
E6 oncogene-mediated P53 degradation in 
HPV 16 positive cells in oral cancer throughout 
carcinogenesis (50). It also down-regulates 
the expression of uPA, COX2, NOS, LOX, MMP-
9, and TNF chemokines (50).  
Epigallocatechin gallate (EGCG):  
 Tea is one the world most consumed 
non-alcoholic beverages. The major tea 
cathecins are epigallocatechingallate (EGCG), 
epicathechingallate (ECG), epicatechin (EC) 
and epigallocatechin (EGC) (51). ECGC repre- 
sents over 40% of all green tea catechins and 
it plays a key role in the prevention of cancer, 
obesity, neurodegenerative disorders, and 
stroke (52). The cancer prevention capability 
of EGCG is largely supported by epidemio- 
logical, invivo and invitro studies (53). Despite 
adequate evidence of EGCG effects against 
liver, breast and prostatic cancers, its effects 
on cervical cancer prevention is however 
controversial and still inconclusive (54). 
 EGCG has been reported to induce 
mitosis (G1, G2, S and M) arrest in squamous 
Me180 cervical carcinoma cell at low 
concentration (0-25µg/mL) (55). Another 
study showed that EGCG also mediated G1 
phase arrest in CaSki cells linked to HPV 16 
and regulated gene expressions (56). The 
activation of epidermal growth factor receptor 
(EGFR) and its downstream target, 
extracellular signal regulated protein kinases 
(ERK1/2), is important during cancer cell 
proliferation (57). Through the level of P53 
and CKI, EGCG inactivate EGFR and ERK1/2 
protein kinases causing G1 arrest and 
increased apoptosis in several cervical cell 
lines (57). Studies showed that EGCG inhibits 
the proliferation of cervical adenocarcinoma, 
due to its effects on PK-i67 and suppression of 
telomerase function, thereby inducing apo- 
ptosis (58). Current researches also reveal 
that EGCG through telomerase, a reverse 
transcriptase, telomerase which adds new 
DNA to the telomeres at the end of the 
chromosomes (58), and RNA polymerase III, 
could control the growth of cancer cells (58). 
Carageenan    
 Carageenan prevents the binding of 
HPV virions to the basal cells of the cervix, 
thereby preventing viral pathogenesis. 
Nordihydroguaiaretic acid   
 Nordihydroguaiaretic acid is an active 
compound from Lignan plant, which inhibits 
HPV SP1-mediated transcription. 
Echinacea purpurae   
 Echinacea purpurae is one of the most 
favourite medicinal plants in the world, 
belonging to the family Astracea. It is 
commonly used as a chemo-preventive and 
chemotherapeutic plant especially in upper 
respiratory tract. It is also used in treatment 
of cancer such as cervical cancer and serves 
as immunomodulator. Although investigators 
have noted the isolation and structural 
elucidation of its main compound, there is no 
conclusion about its mechanism of action 
(59).      
 The active ingredients are alkamide, 
caffeic acid and polysaccharides. The alkamide 
is reported to be responsible for plant 
immunomodulatory property which uses T-cell 
activation and enhances the production of TNF 
and IFN-y. Its antiviral properties can also be 
linked to the fact that it inhibits hyaluro- 
nidases produced by viruses while the 
polysaccharide is responsible for its anti-
inflammatory effects (28). Caffeic acid, 
however, is not present in all Echinacea 
species and could be used for plant extract 
authentication and quality control (59). 
Immunomodulatory activity of Echinacea
 The immunostimulant properties of 
the plant involve three mechanisms: phago- 
cytosis activation, fibroblast stimulation, and 
increased respiratory activity resulting in 
increased leucocyte migration. There are 
different studies that have reported the invivo 
immunomodulatory and anti-inflammatory 
properties of Echinacea purpurae suggesting 
enhanced innate immunity when the plant is 
administered and increased immune response 
by stimulating macrophages, polymorpho- 
nuclear leucocytes (PMN), and natural killer 
(NK) cells (60). It is thus an effective 




preventive measure for the treatment of 
various infectious diseases such as infections 
of the respiratory tract, wound and pelvis 
(61).      
 The complex chemical composition of 
Echinacea roots and herbs contain keto- 
alkenes, alkamides, caffeic acid derivatives, 
polysaccharides and glycoproteins which are 
allegedly responsible for noted immuno- 
stimulatory and anti-inflammatory activities 
(60). The alkamides have been tested and 
documented to be acting on type 2 
cannabinoid receptors (CB2), and this is also 
hypothesized as possible mechanism for their 
immunomodulatory properties (62). One 
research has shown that N-alkamides 
obtained from root and herbal tincture 
induced synergistic properties on CB2 and 
eventually contribute to the immuno- 
modulatory effects along with interleukin 10 
(63). They also inhibit both cyclo-oxygenase 
enzymes (COX-1 and COX-2) and 5-lipo- 
oxygenase (F-LO), enabling natural cell 
inhibition and anti-inflammatory activity (64). 
It is reported that the plant portion 
(polysaccharides) increases the production of 
interleukin-1 (IL-1), interleukin-6 (IL-6) and 
TNF-α by macrophages, and also increase 
their phagocytic and microbicide activity, and 
cerebrospinal fluid secretion (65).  
 The expression of CD83, which is a 
marker of dendritic cell maturation, has been 
shown to be significantly enhanced by the 
plant’s floral and root extracts, while the stem 
and leaf extracts can significantly decrease 
CD83 levels. In addition, studies have shown 
that the extracts from the plant’s root and 
aerial section require up and down regulation 
of insulin-like growth factor 1 receptor (IGF-
1R), respectively. In addition, the plant’s root 
extract can control a variety of genes involved 
in immune cell activation or function including 
Chemokine (C-C motif) ligand 4 (CCL4), 
interleukin-7 receptor,  nuclear factor of 
activated T-cells, cytoplasmic 2, T-box trans- 
cription factor, cytohesin-interacting protein 
(PSCDBP), integrin, alpha E (ITGAE), and 
intercellular adhesion molecule-1 (ICAM1), 
while CD34 and integrin beta-1 (ITG-B1) are 
down regulated by the aerial part of the plant 
extract in dendritic cells (DCs) (66). 
Cytotoxic activity of Echinacea  
 It has been documented that the plant 
extract flower and cichoric acid inhibit both the 
human colon cancer cell lines, Caco-2 and 
HCT-16, in a dose dependent manner after 48 
hours of exposure. It has also been reported 
that cichoric acid slows down the HCT-16 cell 
line telomerase activity, which could be 
presumed as the molecular mechanism of 
apoptosis indication (67). Nonetheless, an 
extract from the plant root known as n-hexane 
that can be obtained from three species of 
Echinacea has been shown to have potent 
anticancer activity (68).   
Lethal dosage of Echinacea in animal studies
 Animal studies of various preparations 
of Echinacea species showed generally low 
toxicity (69). In acute toxicity test, the LD50 
value was estimated at 2500 mg/kg in an 
intraperitoneal injection of the plant’s 
polysaccharides fraction into female mice 
(69). In other studies, oral and intravenous 
LD50 values for plant juice were estimated to 
exceed 30g/kg and 10g/kg in mice, and 
15g/kg and 5g/kg in rats (70). 
Antiviral activity of Echinacea  
 In an invitro study, aqueous solution 
from the plant extract of Echinacea purpurae 
was confirmed to be active against both 
acyclovir resistant and susceptible strains of 
herpes simplex virus 1 (HSV 1) and herpes 
simplex virus 2 (HSV 2) (71), whereby, the 
plant root hexane extract and cichoric acid 
exhibited HSV 1 inhibition (72). Furthermore, 
cichoric acid has been reported to inhibit 
integrase activity of human immunodeficiency 
virus type 1 (HIV-1) (73). Mouse embryonic 
fibroblasts incubated with the plant juice and 
alcoholic root extract was immuned to 
influenza A2, herpes, and 24-hour infection of 
the vesicular stomatitis virus (74).                        
 Normal preparation of the plant 
extract showed strong inhibition of the 
influenza viruses A/Victoria/75 (H3N2) and 
A/Puerto Rico/8/1934 (H1N1), avian strains 
A/Thailand/1(KAN-1)/2004 (H5N1) and A/ 
FPV/Dutch/1927 (H7N7), and the pandemic 
novel influenza A (S-OIV) (H1N1) of swine 
origin in direct contact. Nonetheless, haem- 
agglutination (HA) assays showed that the 
preparation inhibited HA activity, and thus 
prevented the virus from entering the treated 
cells (75). 
Conclusion: 
 This review highlighted the improve- 
ment in the design of anti-HPV, as well as 
potential therapy regimen for HPV infections 
in Nigeria and globally, using phytotherapeutic 
approaches. HPV being a major cause of 
cervical cancer, and cervical cancer being one 
of the leading causes of annual death in adult 
women, prevention of cervical cancer is 
possible by seeking a cost-effective treatment 
for the main causative agent, HrHPV. The 
main antiviral therapy against HPV is cidofovir 
(CDV), which in addition to being expensive, 
has side effects ranging from renal to ocular 
disturbances.     
 While alternative medicine approa- 
ches for therapy of cervical cancer ranges 




from globally accepted homeopathic methods 
to the allopathic approach embraced by the 
Indians, Chinese, and Japanese to treat HPV-
related diseases, their mechanisms of action 
are not established. Therefore, more studies 
on antiviral agents against HPV are required. 
It has been reported that herbal therapy such 
as Echinacea not only reduce viral replication 
but also enhance the immune system, with 
the prospect of easy accessibility and 
affordability in Nigeria. Although there is no 
scientific explanation for the efficacy of 
Echinacea therapy against HPV infections at 
present, there need for more researches in 
this area. 
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